Acutaas Chemicals Ltd
Acutaas Chemicals Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
The company targets a 25% revenue growth for the full year FY '26, maintaining confidence despite achieving 21% growth in H1 FY '26. The company expects sustainable EBITDA margins of 28% to 30% in FY '26 and beyond, driven by improved product mix, higher contribution from CDMO business, and operational efficiencies (Page 14). - Revenue growth guidance is maintained at around 25% for FY '26, backed by a robust CDMO pipeline, pharmaceutical intermediates, and new verticals like electrolyte additives and semiconductor chemicals (Pages 6, 12, 14). - New CDMO products are expected to start contributing by end of FY '26, post regulatory approvals (Page 6). - Electrolyte additive plant commissioning by Q4 FY '26 and full commercial contribution expected in FY '27, with South Korea JV beginning production in H2 FY '27 (Pages 7, 14, 15). - Operational improvements and solar plant contribution are expected to support margin and profit growth (Page 6). - Capital expenditures focused on growth (INR 210 crores approx.
From Acutaas Chemicals Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company targets a 25% revenue growth for the full year FY '26, maintaining confidence despite achieving 21% growth in H1 FY '26.
- Higher growth is expected from the CDMO business segment compared to traditional Pharma Intermediates.
- Electrolyte additives segment is expected to start contributing from Q4 FY '26 and more significantly in FY '27, with full visibility on capex and products.
- Semiconductor JV in South Korea is projected to start commercial production in H2 FY '27, contributing to revenue thereafter.
- Specialty Chemicals segment is expected to grow around 10-15% in FY '26.
- No specific revenue disclosure for new segments, but significant growth drivers identified in CDMO, battery chemicals, and semiconductor chemicals in the coming years.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Acutaas Chemicals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY '26 capex planned around INR 250 crores, with INR 40 crores for maintenance and the rest for growth.
- Major growth capex includes INR 180 crores for electrolyte additive plant at Jaghadia and INR 30 crores for pilot plant at Sachin.
- Electrolyte additive capex expected to complete by Q4 FY '26 and start contributing from Q4 FY '26, fully ramping by FY '27.
- South Korea JV (Indichem) capex underway, commercial production expected in H2 FY '27; Acutaas holds 75% stake.
- Beyond FY '26, all planned growth capex expected to be completed; future capex to be mainly maintenance.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Acutaas Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Validation batches for new CDMO contracts have been sent during the quarter.
- Commercial production for these new CDMO products is expected to start by the last quarter of FY '26, subject to regulatory approvals.
- Full visibility exists for the CDMO business for the current year and projections for the next years, indicating a healthy order book.
- The Block 3 at Ankleshwar, commissioned last year, is operational and catering to projected customer requirements.
- For electrolyte additives, the planned capacity (2,000 metric tons each for VC and FEC) is based on signed contracts, providing full visibility on demand.
2 more points management made on order book & pipeline
Acutaas Chemicals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹433 Cr, net profit ₹134 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Acutaas Chemicals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Morepen Laboratories Ltd (Q2 FY26)
248 Crores . Key concall takeaways from Morepen Laboratories Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q2 FY26)
Q2’FY26 revenue grew by 12% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
- Anuh Pharma Ltd (Q2 FY26)
185.88 Cr, a -0.32% change quarter-on-quarter; 6 months ended 30/09/2025: Rs. Key concall takeaways from Anuh Pharma Ltd's Q2 FY26 earnings call — and how it…
- Themis Medicare Ltd (Q2 FY26)
Q2 FY26 Net Revenue: ₹77.99 Cr, down 33.3% YoY from ₹117.01 Cr in Q2 FY25 (Page 8) . Key concall takeaways from Themis Medicare Ltd's Q2 FY26 earnings call…
Frequently Asked Questions
What were Acutaas Chemicals Ltd Q2 FY26 results?
The company targets a 25% revenue growth for the full year FY '26, maintaining confidence despite achieving 21% growth in H1 FY '26. The company expects sustainable EBITDA margins of 28% to 30% in FY '26 and beyond, driven by improved product mix, higher contribution from CDMO business, and operational efficiencies (Page 14). - Revenue growth guidance is maintained at around 25% for FY '26, backed by a robust CDMO pipeline, pharmaceutical intermediates, and new verticals like electrolyte additives and semiconductor chemicals (Pages 6, 12, 14). - New CDMO products are expected to start contributing by end of FY '26, post regulatory approvals (Page 6). - Electrolyte additive plant commissioning by Q4 FY '26 and full commercial contribution expected in FY '27, with South Korea JV beginning production in H2 FY '27 (Pages 7, 14, 15). - Operational improvements and solar plant contribution are expected to support margin and profit growth (Page 6). - Capital expenditures focused on growth (INR 210 crores approx.
What is Acutaas Chemicals Ltd share price analysis?
Acutaas Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 69.6 with a market cap of ₹26,877 Cr. Investors should review the full earnings analysis for detailed insights.
Is Acutaas Chemicals Ltd planning capital expenditure?
FY '26 capex planned around INR 250 crores, with INR 40 crores for maintenance and the rest for growth.
Keep Acutaas Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.